For the treatment of asymptomatic hyperuricemia, almost all guidelines agree that non-pharmacological treatment should be given, and there is no agreement on whether or not pharmacological treatment should be given. 2010 Chinese gout guidelines suggest that non-pharmacological treatment is the mainstay for asymptomatic hyperuricemia, and uric acid-lowering drugs are generally not recommended. However, in patients whose blood uric acid is higher than 9 mg/dl even after dietary control, or whose blood uric acid is higher than 8 mg/dl with family history or associated diseases, uric acid-lowering therapy can be given. The “Chinese Expert Consensus on Asymptomatic Hyperuricemia”, initiated by Chinese experts in 2012, is very positive about the application of uric acid-lowering drugs. Patients with cardiovascular risk factors or comorbidities and blood uric acid levels greater than 8mg/dl should be treated with uric acid-lowering drugs, and patients with hyperuricemia with blood uric acid levels less than 8mg/dl should be treated with uric acid-lowering drugs if they are still higher than normal after 6 months of life guidance; 2. given uric acid-lowering medication, and patients with less than 9 mg/dl should be recommended to add uric acid-lowering medication if it is still higher than normal after 6 months of life guidance. Cardiovascular comorbidities or risk factors include: hypertension, abnormal glucose tolerance or diabetes, hyperlipidemia, coronary artery disease, stroke, heart failure, or renal abnormalities. The consensus is very positive for uric acid-lowering drug therapy mainly because of the findings of the numerous studies on the dangers of hyperuricemia that people have conducted in recent years – hyperuricemia is an independent risk factor for hypertension, coronary heart disease, stroke, all-cause mortality in the general population, death from coronary heart disease, cardiovascular events, and death from acute and chronic heart failure. Among them, there is a global consensus that hyperuricemia is an independent risk factor for cardiovascular disease.